Impact Factor
3.63
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.45
1,175 total citations
h5-index
33
h5 depth signal
Cited share
76.0%
272 of 358
Total citations
1,175
Citation footprint
Metric signal
3.04
External metric anchor
Self-citation
5.8%
68 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
935
United Kingdom
293
Canada
162
Switzerland
117
Netherlands
98
Citing Fields of Research
Medical Ethics
301
Cardiology
193
Healthcare Policy
175
Oncology
174
Hematology
143
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,779
Articles tracked across the journal lifetime
Indexed publication set
358
272 cited publications
Last 12 months
229
19.1 publications/month
Open access share
100.0%
229 OA publications in the last year
Leading citing country
United States
935 citing publications
Leading citing field
Medical Ethics
301 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v11n1, 2008-
v11n1, 2008-
Research Focus & Classification
Indexed Subjects
Cardiology
Medical Ethics
Oncology
Healthcare Policy
Lung Cancer
Lymphomas
Hematology
Broad Categories
Health Services
Cardiology
Medical Ethics
Urology
Virology
Musculoskeletal Disorders
Lung Cancer
MeSH Descriptors
Costs and Cost Analysis
Economics, Medical
Economics, Pharmaceutical
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/13696998.2026.2746277
Open DOI
Cost‑effectiveness analysis of the mRNA‑1345 RSV vaccine for older adults in Italy
02
03
04
DOI 10.1080/13696998.2026.2745423
Open DOI
From drug comparison to population health impact: rethinking value assessment in health technology evaluation
05
06
DOI 10.1080/13696998.2026.2745425
Open DOI
Insurance and altruism values of a novel treatment for hypophosphatasia: a stated preference survey in the United States
Many healthcare decision makers use the incremental cost-effectiveness ratio (ICER) derived from cost-effectiveness analysis (CEA) to inform pricing through health technology assessment (HTA).1 Tra...
07
DOI 10.1080/13696998.2026.2746286
Open DOI
Correction
08
DOI 10.1080/13696998.2026.2740956
Open DOI
Attack severity in hereditary angioedema: a qualitative study to inform future economic evaluations
Hereditary angioedema (HAE) is a rare condition with unpredictable, potentially life-threatening swelling attacks. Severity classifications in economic evaluations of new treatments often rely on parameters such as attack duration or ADL...
09
10
DOI 10.1080/13696998.2026.2736995
Open DOI
Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in Sweden
Haemophilia B is a rare X-chromosome linked bleeding disorder characterised by a deficiency of coagulation factor IX (FIX)1,2. In 2023, haemophilia B resulted in an estimated 38,000 cases worldwide...
Bibliographical & Catalog Notes
Description based on: Vol. 10, issue 2 (2007).
Latest issue consulted: Vol. 10, issue 4 (2007).
Also issued online.